VIKEN, Sweden, August 31, 2022 /PRNewswire/ — TikoMed, a biopharmaceutical company focused on harnessing the medical potential of the body’s ability to self-repair and regenerate, today announced the publication in Frontiers in Phamacology of peer-reviewed research peers supporting the unique broad-spectrum mechanism of action of TikoMed ILB® Neuroprotective Drug Platform. In multiple preclinical and clinical studies involving a variety of neuroinflammation-induced diseases, the low molecular weight dextran sulfate compound has both mobilized and modulated natural tissue repair mechanisms and restored homeostasis and function. cells by releasing heparin-binding growth factors. TikoMed believes this approach to enhancing the body’s self-repair and regenerative abilities has the potential to transform current cell and gene therapy paradigms.
“These studies show that ILB® releases, redistributes and modulates the bioactivity of endogenous heparin-binding growth factors that target disease-compromised nerve tissue to initiate a cascade of transcriptional, metabolic and immunological effects that play a key role in controlling glutamate toxicity, normalizing tissue bioenergetics and resolving inflammation to improve tissue function.ILB®’s unique mechanism of action supports the treatment potential of various acute and chronic neurodegenerative diseases, including sTBI and ALS”, said Ann Logan, scientific director at Axolotl Consulting and professor of regenerative medicine at the University of Warwick.
In summary, the studies have provided evidence that ILB® has a profound therapeutic effect on the molecular and cellular dysfunctions underlying neurodegenerative diseases. Gene expression analysis demonstrated substantial similarities in functional dysregulation induced by severe traumatic brain injury (sTBI) and various human neurodegenerative conditions, including ALS. Changes in gene expression after ILB® treatment supported a beneficial cascading effect of ILB® on growth factor activation, resulting in the observed therapeutic effect. The transcriptional signature after ILB® treatment is relevant to cell survival, inflammation, glutamate signaling, metabolism and synaptogenesis, and is consistent with the activation of neuroprotective growth factors. The ability of ILB® to elevate circulating levels of heparin-binding growth factors in animal models and humans also supports its neuroprotective and regenerative effects in vivo.
“ILB® is currently being developed both as a therapeutic and as an enabling technology for advanced therapies, and this peer-reviewed research indicates even broader potential. We have initiated development programs for amyotrophic lateral sclerosis (ALS), traumatic brain injury (TBI) and islet cell transplantation and will now consider broader use in a wider range of diseases,” said Anders KristenssonCEO of TikoMed.
Contact: [email protected] or +46 42 23 84 40
International: Richard Hayhurst [email protected] or +44 7711 821527
Nordics: Ola Bjorkman [email protected] or +46 70 245 7497
This information was brought to you by Cision http://news.cision.com